A recent study indicates that patients who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end conventional lifestyle programs.
Published data in a leading medical journal points out that while obese people can lose substantial amounts of their body weight while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.
"Users buying such medications should be cognizant of the danger of fast weight regain when the treatment concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain means a reversion to original weight within about a year and a half.
Weighing Therapies
The study, which reviewed 37 of trials involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team note that individuals who lose weight through lifestyle changes alone typically have a more gradual weight regain—approximately 100 grams monthly—after stopping.
Understanding the Quick Rebound
Nutrition scientists believe the way of the injections accounts for the heightened weight return.
These medications mimic a body's own chemical called GLP-1, which moderates feelings of fullness.
"Artificially providing GLP-1 levels far above than the body's typical production might result in the body to produce less of its endogenous GLP-1, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a dietetics researcher.
"Stopping of this GLP-1 'fix' means hunger is uncontrolled, making overeating a significant risk."
A Chronic Disease?
Medical guidelines advise the jabs for individuals with weight-linked medical conditions, alongside recommended lifestyle changes.
A number of clinicians argue that, due to the likelihood of weight regain, the treatment is often life-long.
This opinion is reinforced by drug manufacturers, who state that the findings "underscore the chronic nature of excess weight," comparing it to managing diseases like hypertension.
User Accounts
Individuals who have come off the jabs describe a intense return of hunger.
"It was like something that goes on and I was suddenly starving," said a patient.
This difficulty is exacerbated if users have not developed lasting dietary or behavioural changes during therapy.
Widespread Use
Figures indicate that a significant number of adults in the UK have tried these injections in the past year, with interest continuing to grow.
- Adoption is greater among females compared to men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion access the medications through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent tools for shedding pounds, they are not a magic solution and maintained weight loss relies on combined behavioural changes.
